$2.85 Billion is the total value of Vivo Capital, LLC's 63 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 166.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TIL | New | Instil Bio Inc | $313,169,000 | – | 12,486,787 | +100.0% | 11.01% | – |
| BOLT | New | Bolt Therapeutics Inc | $127,404,000 | – | 3,871,291 | +100.0% | 4.48% | – |
| EPIX | Buy | Essa Pharma Inc | $60,102,000 | +166.0% | 2,068,907 | +9.2% | 2.11% | +109.5% |
| TERN | New | Terns Pharmaceuticals Inc | $58,853,000 | – | 2,675,133 | +100.0% | 2.07% | – |
| KALV | Buy | KalVista Pharmaceuticals Inc. | $47,868,000 | +55.8% | 1,863,296 | +15.1% | 1.68% | +22.7% |
| GRCL | New | Gracell Biotechnologies Incsponsored ads | $23,454,000 | – | 1,522,994 | +100.0% | 0.82% | – |
| AKRO | Buy | Akero Therapeutics Inc | $19,532,000 | +19.5% | 673,280 | +6.3% | 0.69% | -5.9% |
| CRIS | Buy | Curis Inc | $17,586,000 | +53.4% | 1,553,500 | +11.0% | 0.62% | +20.7% |
| DSGN | New | Design Therapeutics | $15,877,000 | – | 530,991 | +100.0% | 0.56% | – |
| CGEM | New | Cullinan Management Inc | $10,418,000 | – | 250,000 | +100.0% | 0.37% | – |
| ASLN | New | Aslan Pharmaceuticals Ltdads | $9,517,000 | – | 2,840,909 | +100.0% | 0.33% | – |
| DYN | Buy | Dyne Therapeutics Inc | $8,971,000 | +35.6% | 577,642 | +83.4% | 0.32% | +6.8% |
| IMVT | Buy | Immunovant Inc | $8,547,000 | -46.8% | 532,847 | +53.3% | 0.30% | -58.2% |
| STSA | New | Satsuma Pharmaceuticals Inc | $7,283,000 | – | 1,232,394 | +100.0% | 0.26% | – |
| SNDX | New | Syndax Pharmaceuticals Inc | $7,155,000 | – | 320,000 | +100.0% | 0.25% | – |
| MRUS | New | Merus NV | $3,656,000 | – | 175,000 | +100.0% | 0.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.